首页> 外文期刊>Journal of Ethnopharmacology: An Interdisciplinary Journal Devoted to Bioscientific Research on Indigenous Drugs >An herbal fruit, Amomum xanthoides, ameliorates thioacetamide-induced hepatic fibrosis in rat via antioxidative system.
【24h】

An herbal fruit, Amomum xanthoides, ameliorates thioacetamide-induced hepatic fibrosis in rat via antioxidative system.

机译:一种草药水果,砂仁砂仁,可通过抗氧化系统改善硫代乙酰胺诱导的大鼠肝纤维化。

获取原文
获取原文并翻译 | 示例
       

摘要

AIM OF THE STUDY: Amomum xanthoides is a well-known traditional herbal medicine mainly for diverse digestive system disorders in Asia for a long time. In the present study, we investigate the effects and action mechanism of methanol fraction of Amomum xanthoides (MFAX) on thioacetamide (TAA)-induced liver fibrosis in rat model. MATERIALS AND METHODS: TAA (200mg/kg, ip on twice a week for 14 weeks) treated rats were orally administered with MFAX (25, 50 or 100mg/kg) once a day from the 7th week until 14th week. RESULT: Significantly elevated serum bilirubin, liver tissue hydroxyproline and malondialdehyde (MDA) in liver fibrosis were ameliorated by MFAX treatment. Further, MFAX treatment attenuated the reactive oxygen species (ROS) levels and restored glutathione (GSH) content and glutathione-peroxidase (GPx) activity. Histopathological data showed that MFAX treatment inhibited collagen accumulation and activation of hepatocyte stellate cells (HSCs) in the liver tissue. Compared to the TAA group, activation of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha), transforming growth factor beta (TGF-beta), platelet-derived growth factor beta (PDGF-beta) mRNAs and the level of pro-fibrotic cytokines PDGF-beta and connective tissue growth factor (CTGF) in the liver tissue were attenuated in MFAX treated groups. CONCLUSION: The above evidences collectively indicate that MFAX is a potential herb which can be used as an anti-hepatofibrotic remedy.
机译:研究目的:砂仁是一种著名的传统草药,长期以来主要用于亚洲的多种消化系统疾病。在本研究中,我们调查砂仁中的甲醇部分(MFAX)对硫代乙酰胺(TAA)诱导的大鼠肝纤维化的作用及其作用机理。材料与方法:从第7周至第14周,每天一次口服经TAA(200mg / kg,每周两次,连续14周腹膜内注射)的MFAX(25、50或100mg / kg)。结果:MFAX治疗可明显改善肝纤维化患者的血清胆红素,肝组织羟脯氨酸和丙二醛(MDA)。此外,MFAX处理减弱了活性氧(ROS)的水平,并恢复了谷胱甘肽(GSH)含量和谷胱甘肽过氧化物酶(GPx)活性。组织病理学数据表明,MFAX处理可抑制胶原蛋白的积累和肝组织中肝细胞星状细胞(HSC)的活化。与TAA组相比,诱导型一氧化氮合酶(iNOS),肿瘤坏死因子α(TNF-alpha),转化生长因子beta(TGF-beta),血小板源性生长因子beta(PDGF-beta)mRNA的激活和在MFAX治疗组中,肝组织中促纤维化细胞因子PDGF-β和结缔组织生长因子(CTGF)的水平降低。结论:以上证据共同表明MFAX是一种潜在的草药,可用作抗肝纤维化药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号